Immigrés en Europe : politiques locales d'intégration / la Documentation française ; sous la dir. de Didier Lapeyronnie

Collection : Les études de la Documentation française

Almanach général des marchands, négocians et commerçans de la France et de l'Europe : contenant l'état des principales villes commerçantes, la nature des marchandises ou denrées qui s'y trouvent, les différentes manufactures ou fabriques relatives au commerce, avec les noms de leurs principaux marchands, négocians, fabriquants, banquiers, artistes, &c.

1786 (SUPPL).

Almanach général des marchands, négocians et commerçans de la France et de l'Europe : contenant l'état des principales villes commerçantes, la nature des marchandises ou denrées qui s'y trouvent, les différentes manufactures ou fabriques relatives au commerce, avec les noms de leurs principaux marchands, négocians, fabriquants, banquiers, artistes, &c.

Variante(s) de titre : Almanach général des marchands, négociants et commerçants de la France et de l'Europe

Zoonotic occupational diseases in forestry workers: Lyme borreliosis, tularemia and leptospirosis in Europe

INTRODUCTION: Forestry workers and other people who come into close contact with wild animals, such as hunters, natural science researchers, game managers or mushroom/berry pickers, are at risk of contracting bacterial, parasitological or viral zoonotic diseases. Synthetic data on the incidence and prevalence of zoonotic diseases in both animals and humans in European forests do not exist. It is therefore difficult to promote appropriate preventive measures among workers or people who come into direct or indirect contact with forest animals. OBJECTIVES: The objectives of this review are to synthesise existing knowledge on the prevalence of the three predominant bacterial zoonotic diseases in Europe, i.e. Lyme borreliosis, tularemia and leptospirosis, in order to draw up recommendations for occupational or public health. METHODS: 88 papers published between 1995-2013 (33 on Lyme borreliosis, 30 on tularemia and 25 on leptospirosis) were analyzed. CONCLUSIONS: The prevalences of these three zoonotic diseases are not negligible and information targeting the public is needed. Moreover, the results highlight the lack of standardised surveys among different European countries. It was also noted that epidemiological data on leptospirosis are very scarce.

Zoonoses professionnelles chez les forestiers : le point sur la borréliose de Lyme, tularémie et leptospirose en Europe

L'objectif de ce travail était d'établir une revue synthétique de la littérature concernant la situation de 3 zoonoses professionnelles en milieu forestier, à savoir la borréliose de Lyme, la tularémie et la leptospirose. Quatre-vingt-trois articles ont été utilisés pour la rédaction de ce travail, dont 30 traitaient spécifiquement de la borréliose de Lyme, 30 de la tularémie et 24 de la leptospirose. Une connaissance générale de chacune des zoonoses, notamment des vecteurs, hôtes et moyens de transmission, est nécessaire pour une bonne compréhension de la problématique et pour établir des mesures préventives adaptées. La situation épidémiologique de chacune d'entre elles est discutée à la fois chez les animaux et l'homme en Europe, puis plus spécifiquement chez les forestiers. Les études menées depuis 1995, s'appuyant principalement sur des analyses séroépidémiologiques, confirment le risque professionnel lié à ces 3 zoonoses chez les forestiers. Elles restent cependant insuffisantes pour quantifier ce risque. Le manque de données épidémiologiques à disposition, notamment pour la tularémie et la leptospirose, à la fois chez les animaux et l'homme, limite considérablement l'évaluation de leurs conséquences. Ce travail permet un aperçu rapide, clair et complet de ces 3 zoonoses professionnelles auxquelles les forestiers sont exposés en Europe et aidera à sensibiliser les professionnels de la santé et les travailleurs du secteur forestier à cette problématique ainsi qu'à la gestion et prévention des risques.

Meckel-Gruber Syndrome: a population-based study on prevalence, prenatal diagnosis, clinical features, and survival in Europe.

Meckel-Gruber Syndrome is a rare autosomal recessive lethal ciliopathy characterized by the triad of cystic renal dysplasia, occipital encephalocele and postaxial polydactyly. We present the largest population-based epidemiological study to date using data provided by the European Surveillance of Congenital Anomalies (EUROCAT) network. The study population consisted of 191 cases of MKS identified between January 1990 and December 2011 in 34 European registries. The mean prevalence was 2.6 per 100 000 births in a subset of registries with good ascertainment. The prevalence was stable over time, but regional differences were observed. There were 145 (75.9%) terminations of pregnancy after prenatal diagnosis, 13 (6.8%) fetal deaths, 33 (17.3%) live births. In addition to cystic kidneys (97.7%), encephalocele (83.8%) and polydactyly (87.3%), frequent features include other central nervous system anomalies (51.4%), fibrotic/cystic changes of the liver (65.5% of cases with post mortem examination) and orofacial clefts (31.8%). Various other anomalies were present in 64 (37%) patients. As nowadays most patients are detected very early in pregnancy when liver or kidney changes may not yet be developed or may be difficult to assess, none of the anomalies should be considered obligatory for the diagnosis. Most cases (90.2%) are diagnosed prenatally at 14.3±2.6 (range 11-36) gestational weeks and pregnancies are mainly terminated, reducing the number of LB to one-fifth of the total prevalence rate. Early diagnosis is important for timely counseling of affected couples regarding the option of pregnancy termination and prenatal genetic testing in future pregnancies.

Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe.

Since its introduction to the market in 1985, mefloquine has been used for malaria chemoprophylaxis by more than 35 million travellers. In Europe, in 2014, the European Medicines Agency (EMA) issued recommendations on strengthened warnings, prescribing checklists and updates to the product information of mefloquine. Some malaria prevention advisors question the scientific basis for the restrictions and suggest that this cost-effective, anti-malarial drug will be displaced as a first-line anti-malaria medication with the result that vulnerable groups such as VFR and long-term travellers, pregnant travellers and young children are left without a suitable alternative chemoprophylaxis. This commentary looks at the current position of mefloquine prescribing and the rationale of the new EMA recommendations and restrictions. It also describes the new recommendations for malaria prophylaxis that have been adapted by Switzerland, Germany, Austria and Italy where chemoprophylaxis use is restricted to high-risk malaria-endemic areas.